Literature DB >> 3132387

Susceptibility of stably derepressed beta-lactamase producing strains to imipenem and four quinolones.

R N Jones, A L Barry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3132387     DOI： 10.1007/bf01962184

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  9 in total

1.  Incidence of inducible beta-lactamases in gram-negative septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.

Authors: 
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 2.  Clinical importance of inducible beta-lactamases in gram-negative bacteria.

Authors:  C C Sanders; W E Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

3.  Clinical consequences of development of resistance to third generation cephalosporins.

Authors:  F Follath; E Costa; A Thommen; R Frei; A Burdeska; J Meyer
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

4.  Selection and properties of Pseudomonas aeruginosa variants resistant to beta-lactam antibiotics.

Authors:  W Cullman; K H Büscher; W Dick
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 5.  Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.

Authors:  D M Livermore
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

6.  Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  In vitro evaluation of U63196-E (AC-1370): antimicrobial activity, beta-lactamase stability, and beta-lactamase inhibition.

Authors:  R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1984-04       Impact factor: 2.803

8.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

9.  Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins.

Authors:  D L Dworzack; M P Pugsley; C C Sanders; E A Horowitz
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267
  9 in total
  3 in total

1.  In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.

Authors:  M E Erwin; R N Jones; M S Barrett; B M Briggs; D M Johnson
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.

Authors:  D M Johnson; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

3.  In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.